Radioimmunotherapy: Development of an effective approach. Progress report, 1987
Goals of this program are to answer the fundamental scientific questions for the development of an effective approach for delivering radiation therapy to cancer on antibody-based radiopharmaceuticals. The following list consists of highlights of developments from our program: documented therapeutic response of lymphoma in patients receiving radioimmunotherapy; development and application of quantitative radionuclide imaging techniques for therapy planning and dosimetry calculations; multicompartmental modeling and analysis of the in vivo MoAb kinetics in patients; a MoAb macrocycle chelate for Cu-67: development, production, in vitro and in vivo testing; NMR analysis of immunoradiotherapeutic effects on the metabolism of lymphoma; analysis of the variable molecular characteristics of the MoAb radiopharmaceutical, and their significance; in vivo studies in mice and patients of the metabolism of radioiodinated MoAb as well as In-111 CITC MoAb; and biodistribution of Cu-67 TETA MoAb in nude mice with human lymphoma.
- Research Organization:
- California Univ., Davis, CA (United States)
- Sponsoring Organization:
- USDOE, Washington, DC (United States)
- DOE Contract Number:
- FG03-84ER60233
- OSTI ID:
- 10121177
- Report Number(s):
- DOE/ER/60233-T4; ON: DE92007627
- Resource Relation:
- Other Information: PBD: [1987]
- Country of Publication:
- United States
- Language:
- English
Similar Records
Radioimmunotherapy: Development of an effective approach
Radioimmunotherapy: Development of an effective approach. Annual report, 1991